The drug regulatory process of the republic of china — taiwan's experiences in bioavailability and bioequivalence

Oliver Yoa pu Hu, Mei Ling Hsiao, li Ling Liu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The drug regulatory process and development of the pharmaceutical industry of the Republic of China in Taiwan has dramatically changed during the last 14 years. Consequently, the pharmaceutical industry, including not only the international giants in Taiwan but the local pharmaceutical manufacturers, has greatly improved both in its research and development as well as in the quality of its products. This report briefly examines the advancement of pharmaceutical affairs in Taiwan. The purpose of this paper is to provide an overview of Taiwan's experiences in the implementation of bioavailability and bioequivalence (BA/BE) which include issues of new regulations, guidelines, concepts, decision rules, and statistical methodology. It also reports the outcomes since the implementation of Taiwanese BA/BE guidelines in November 1987 through September 1994. There were 189 BA/BE reports submitted for review within this period. One hundred and two were performed in Taiwan and 87 were performed in other countries. The approval rates were 64.7% and 40.2%, respectively. The most frequent reasons that BA/BE studies were rejected by the Department of Health was that the AUC ∞ and/or C max did not meet the acceptable criteria. The combination of efforts from academia, government officers, and scientists from the industry was the key to the successful implementation of new and significant improvements in the drug approval system in Taiwan.

Original languageEnglish
Pages (from-to)1049-1054
Number of pages6
JournalTherapeutic Innovation & Regulatory Science
Volume29
Issue number3
DOIs
Publication statusPublished - Jan 1 1995
Externally publishedYes

Fingerprint

Therapeutic Equivalency
Taiwan
Biological Availability
Pharmaceutical Preparations
Drug Industry
Guidelines
Drug Approval
Area Under Curve
Industry
Health
Research

Keywords

  • Bioavailability
  • Bioequivalence
  • Drug regulatory process
  • Republic of China
  • Taiwan

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

The drug regulatory process of the republic of china — taiwan's experiences in bioavailability and bioequivalence. / Hu, Oliver Yoa pu; Hsiao, Mei Ling; Liu, li Ling.

In: Therapeutic Innovation & Regulatory Science, Vol. 29, No. 3, 01.01.1995, p. 1049-1054.

Research output: Contribution to journalArticle

@article{8021b6112962429c890f0581b79eae73,
title = "The drug regulatory process of the republic of china — taiwan's experiences in bioavailability and bioequivalence",
abstract = "The drug regulatory process and development of the pharmaceutical industry of the Republic of China in Taiwan has dramatically changed during the last 14 years. Consequently, the pharmaceutical industry, including not only the international giants in Taiwan but the local pharmaceutical manufacturers, has greatly improved both in its research and development as well as in the quality of its products. This report briefly examines the advancement of pharmaceutical affairs in Taiwan. The purpose of this paper is to provide an overview of Taiwan's experiences in the implementation of bioavailability and bioequivalence (BA/BE) which include issues of new regulations, guidelines, concepts, decision rules, and statistical methodology. It also reports the outcomes since the implementation of Taiwanese BA/BE guidelines in November 1987 through September 1994. There were 189 BA/BE reports submitted for review within this period. One hundred and two were performed in Taiwan and 87 were performed in other countries. The approval rates were 64.7{\%} and 40.2{\%}, respectively. The most frequent reasons that BA/BE studies were rejected by the Department of Health was that the AUC ∞ and/or C max did not meet the acceptable criteria. The combination of efforts from academia, government officers, and scientists from the industry was the key to the successful implementation of new and significant improvements in the drug approval system in Taiwan.",
keywords = "Bioavailability, Bioequivalence, Drug regulatory process, Republic of China, Taiwan",
author = "Hu, {Oliver Yoa pu} and Hsiao, {Mei Ling} and Liu, {li Ling}",
year = "1995",
month = "1",
day = "1",
doi = "10.1177/009286159502900325",
language = "English",
volume = "29",
pages = "1049--1054",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - The drug regulatory process of the republic of china — taiwan's experiences in bioavailability and bioequivalence

AU - Hu, Oliver Yoa pu

AU - Hsiao, Mei Ling

AU - Liu, li Ling

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The drug regulatory process and development of the pharmaceutical industry of the Republic of China in Taiwan has dramatically changed during the last 14 years. Consequently, the pharmaceutical industry, including not only the international giants in Taiwan but the local pharmaceutical manufacturers, has greatly improved both in its research and development as well as in the quality of its products. This report briefly examines the advancement of pharmaceutical affairs in Taiwan. The purpose of this paper is to provide an overview of Taiwan's experiences in the implementation of bioavailability and bioequivalence (BA/BE) which include issues of new regulations, guidelines, concepts, decision rules, and statistical methodology. It also reports the outcomes since the implementation of Taiwanese BA/BE guidelines in November 1987 through September 1994. There were 189 BA/BE reports submitted for review within this period. One hundred and two were performed in Taiwan and 87 were performed in other countries. The approval rates were 64.7% and 40.2%, respectively. The most frequent reasons that BA/BE studies were rejected by the Department of Health was that the AUC ∞ and/or C max did not meet the acceptable criteria. The combination of efforts from academia, government officers, and scientists from the industry was the key to the successful implementation of new and significant improvements in the drug approval system in Taiwan.

AB - The drug regulatory process and development of the pharmaceutical industry of the Republic of China in Taiwan has dramatically changed during the last 14 years. Consequently, the pharmaceutical industry, including not only the international giants in Taiwan but the local pharmaceutical manufacturers, has greatly improved both in its research and development as well as in the quality of its products. This report briefly examines the advancement of pharmaceutical affairs in Taiwan. The purpose of this paper is to provide an overview of Taiwan's experiences in the implementation of bioavailability and bioequivalence (BA/BE) which include issues of new regulations, guidelines, concepts, decision rules, and statistical methodology. It also reports the outcomes since the implementation of Taiwanese BA/BE guidelines in November 1987 through September 1994. There were 189 BA/BE reports submitted for review within this period. One hundred and two were performed in Taiwan and 87 were performed in other countries. The approval rates were 64.7% and 40.2%, respectively. The most frequent reasons that BA/BE studies were rejected by the Department of Health was that the AUC ∞ and/or C max did not meet the acceptable criteria. The combination of efforts from academia, government officers, and scientists from the industry was the key to the successful implementation of new and significant improvements in the drug approval system in Taiwan.

KW - Bioavailability

KW - Bioequivalence

KW - Drug regulatory process

KW - Republic of China

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=84973740917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973740917&partnerID=8YFLogxK

U2 - 10.1177/009286159502900325

DO - 10.1177/009286159502900325

M3 - Article

VL - 29

SP - 1049

EP - 1054

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 3

ER -